肝动脉化疗栓塞结合门静脉癌栓内注药治疗原发性肝癌伴门静脉癌栓临床疗效的初步观察

目的 探讨肝动脉化疗栓塞结合经皮穿刺门静脉癌栓内注药治疗原发性肝癌伴门静脉痛栓的临床价值.方法 30例不能手术切除病灶的原发性肝癌伴门静脉癌栓患者,采用完全随机方法分成A、B组,A组14例,B组16例.治疗前A、B组患者的肝功能Child-Push分级A级均为9例,B级分别为5例和7例(χ~2=0.201,P>0.05);Ⅱ型癌栓A组8例,B组9例,Ⅲ型A组6例,B组7例(χ~2=0.002,P>0.05);A、B两组患者术前丙氨酸氨基转移酶(ALT)中位数分别为58.7和70.5 U/L(W=191.5,P>0.05);总胆红素(TBIL)中位数分别为21.4和21.7 μmol/L(W=203,P>0.05);白蛋白(ALB)中位数分别为35.3和37.5 g/L(W=214,P>0.05);甲胎蛋白(AFP)中位数分别为680和873μg/L(W=179.00,P>0.05),两组相比差异均无统计学意义.A组以肝动脉化疗栓塞治疗肝内原发肿瘤灶,经皮穿刺门静脉癌栓内注药治疗门静脉癌柃;B组单纯肝动脉化疗栓塞治疗.采用Kaplan-Meier计算两组患者的中位生存期,log-rank法检验组间差异.结果 患者治疗后的中位生存期,A组14.0个月、B组4.0个月,两组差异具有统计学意义(χ~2=11.728,P<0.01).患者3、6和12个月的生存数,A组分别为11、10和7例,B组分别为10、3、0例.2组均未见与治疗相关的严重不良反应.结论 与单纯肝动脉化疗栓塞相比,肝动脉化疗栓塞结合经皮穿刺门静脉癌栓内注药治疗,可以显著延长伴有Ⅱ、Ⅲ型门静脉癌栓的原发性肝痛患者的中位生存期.

Preliminary study of the transcatheter arterial chemoembolization in combination of percutaneous injection of chemoembolization agent intra-portal vein tumor thrombosis in treatment of primary hepatic carcinoma accompanied by portal vein tumor thrombosis

Objective To assess the therapeutic outcomes of transcatheter arterial chemoembolization combined with percutaneous injection of chemoembolization agent intra-portal vein tumor thrombosis for primary hepatic carcinoma accompanied by portal vein tumor thrombus. Methods Thirty patients with primary hepatic carcinoma accompanied by portal vein tumor thrombosis of type Ⅱ and type Ⅲ were randomly divided into two groups. The Child-Pugh ratings (class A and B) of group A and B were 9 vs 9 (class A) and 5 vs 7 (class B) respectively (χ~2 = 0.201, P > 0.05). The constitution of Type Ⅱ and type Ⅲ portal vein tumor thrombus in group A and B were 8 vs 9 and 6 vs 7 respectively (χ~2 =0.002, P>0.05). The median values of ALT, TBIL, ALB and AFP in group A and B were 58.7U/L vs 70.5 U/L (W=191.5, P>0.05), 21.4 μmol/L vs 21.7μmol/L (W=203, P>0.05), 35.3 g/L vs 37.5 g/L (W = 214, P > 0.05) and 680 μg/L vs 873 μg/L (W = 179. 00, P > 0.05) respectively. Group A was treated with transcatheter arterial chemoembolization (TACE) using emulsion made up of adriamycin, cisplatin, mitomycin and ultraliquidlipiodol plus percutaneous injection of chemoembolization agent intra-portal vein tumor thrombosis using emulsion consisted of cisplatin and ultraliquidlipiadol, while group B was treated with TACE only as a control group. Survival analyses were performed via the Kaplan-Meier test in SPSS11.5 with the log-rank tests with an threshold of 0.05. Results The 3, 6 and 12 months survival cases of group A and B were 11 vs 10, 10 vs 3, and 7 vs 0 respectively. The median survival time of group A and group B were 14.0 months and 4.0 months respectively. The difference of the two groups was significantly (χ~2 =11.728, P<0.01). There was no severe side-effect related to therapy in both groups. Conclusion Comparing with the control group, TACE combined with percutaneous injection of chemoembolization agent intra-portal vein tumor thrombosis could significantly prolong the median survival time of patient with primary hepatic carcinoma accompanied by type Ⅱ and type Ⅲ portal vein tumor thrombosis.